Joi Ninomoto

915 total citations · 1 hit paper
19 papers, 407 citations indexed

About

Joi Ninomoto is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Joi Ninomoto has authored 19 papers receiving a total of 407 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Genetics, 10 papers in Pathology and Forensic Medicine and 9 papers in Hematology. Recurrent topics in Joi Ninomoto's work include Chronic Lymphocytic Leukemia Research (18 papers), Lymphoma Diagnosis and Treatment (10 papers) and Chronic Myeloid Leukemia Treatments (8 papers). Joi Ninomoto is often cited by papers focused on Chronic Lymphocytic Leukemia Research (18 papers), Lymphoma Diagnosis and Treatment (10 papers) and Chronic Myeloid Leukemia Treatments (8 papers). Joi Ninomoto collaborates with scholars based in United States, Italy and Australia. Joi Ninomoto's co-authors include Thomas J. Kipps, Paul M. Barr, Constantine S. Tam, Danelle F. James, Paolo Ghia, Cathy Zhou, Alessandra Tedeschi, Tanya Siddiqi, William G. Wierda and John N. Allan and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Joi Ninomoto

19 papers receiving 404 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort

2022 124 citations Constantine S. Tam, John N. Allan et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joi Ninomoto United States	11	376	300	148	118	51	19	407
Manuela A. Bergmann Germany	6	562 1.5×	502 1.7×	104 0.7×	239 2.0×	96 1.9×	11	592
Thérèse Aurran France	8	202 0.5×	178 0.6×	40 0.3×	80 0.7×	23 0.5×	19	257
Athanassios Zomas Greece	5	287 0.8×	248 0.8×	116 0.8×	121 1.0×	8 0.2×	6	355
Masa Lasica Australia	11	178 0.5×	130 0.4×	115 0.8×	55 0.5×	15 0.3×	47	323
Juan Besalduch Spain	10	114 0.3×	180 0.6×	150 1.0×	67 0.6×	36 0.7×	23	337
Frank Kauff Germany	6	161 0.4×	244 0.8×	25 0.2×	31 0.3×	31 0.6×	8	273
Ranjit Banwait United States	8	176 0.5×	149 0.5×	73 0.5×	67 0.6×	11 0.2×	25	248
M. Maynadié France	6	118 0.3×	131 0.4×	47 0.3×	37 0.3×	15 0.3×	6	236
Jeffrey P. Sharman United States	7	103 0.3×	94 0.3×	43 0.3×	38 0.3×	22 0.4×	21	165
João Raposo Portugal	5	122 0.3×	159 0.5×	20 0.1×	55 0.5×	13 0.3×	21	202

Countries citing papers authored by Joi Ninomoto

Since Specialization

Citations

This map shows the geographic impact of Joi Ninomoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joi Ninomoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joi Ninomoto more than expected).

Fields of papers citing papers by Joi Ninomoto

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joi Ninomoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joi Ninomoto. The network helps show where Joi Ninomoto may publish in the future.

Co-authorship network of co-authors of Joi Ninomoto

This figure shows the co-authorship network connecting the top 25 collaborators of Joi Ninomoto. A scholar is included among the top collaborators of Joi Ninomoto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joi Ninomoto. Joi Ninomoto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Barr, Paul M., Alessandra Tedeschi, William G. Wierda, et al.. (2022). Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts. Clinical Cancer Research. 28(20). 4385–4391. 6 indexed citations

Tam, Constantine S., John N. Allan, Tanya Siddiqi, et al.. (2022). Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. Blood. 139(22). 3278–3289. 124 indexed citations breakdown →

Coutré, Steven, Christopher F. Barnett, Olayemi Osiyemi, et al.. (2022). Ibrutinib for Hospitalized Adults With Severe Coronavirus Disease 2019 Infection: Results of the Randomized, Double-Blind, Placebo-Controlled iNSPIRE Study. Open Forum Infectious Diseases. 9(5). ofac104–ofac104. 6 indexed citations

Tam, Constantine S., John N. Allan, Tanya Siddiqi, et al.. (2021). CAPTIVATE PRIMARY ANALYSIS OF FIRST‐LINE TREATMENT WITH FIXED‐DURATION IBRUTINIB PLUS VENETOCLAX FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL). Hematological Oncology. 39(S2). 2 indexed citations

Ghia, Paolo, John N. Allan, Tanya Siddiqi, et al.. (2021). First-Line Treatment with Ibrutinib (Ibr) Plus Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL): 2-Year Post-Randomization Disease-Free Survival (DFS) Results from the Minimal Residual Disease (MRD) Cohort of the Phase 2 Captivate Study. Blood. 138(Supplement 1). 68–68. 7 indexed citations

Ghia, Paolo, John N. Allan, Tanya Siddiqi, et al.. (2021). Fixed-duration (FD) first-line treatment (tx) with ibrutinib (I) plus venetoclax (V) for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of the FD cohort of the phase 2 captivate study.. Journal of Clinical Oncology. 39(15_suppl). 7501–7501. 16 indexed citations

Wierda, William G., Constantine S. Tam, John N. Allan, et al.. (2020). Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): 1-Year Disease-Free Survival (DFS) Results From the MRD Cohort of the Phase 2 CAPTIVATE Study. Blood. 136(Supplement 1). 16–17. 31 indexed citations

Ninomoto, Joi, Ahmad Mokatrin, Taisei Kinoshita, et al.. (2020). Effects of ibrutinib on in vitro platelet aggregation in blood samples from healthy donors and donors with platelet dysfunction. Hematology. 25(1). 112–117. 12 indexed citations

Tam, Constantine S., Tanya Siddiqi, John N. Allan, et al.. (2019). Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study. Blood. 134(Supplement_1). 35–35. 31 indexed citations

10.

O’Brien, Susan, John C. Byrd, Peter Hillmen, et al.. (2019). Outcomes with ibrutinib by line of therapy and post‐ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis. American Journal of Hematology. 94(5). 554–562. 22 indexed citations

11.

Wierda, William G., Tanya Siddiqi, Ian W. Flinn, et al.. (2018). Phase 2 CAPTIVATE results of ibrutinib (ibr) plus venetoclax (ven) in first-line chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology. 36(15_suppl). 7502–7502. 20 indexed citations

12.

Barrientos, Jacqueline C., Jan A. Burger, John C. Byrd, et al.. (2018). Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib. Leukemia & lymphoma. 60(4). 1000–1005. 16 indexed citations

13.

Ghia, Paolo, Constantine S. Tam, Tanya Siddiqi, et al.. (2017). AN ONGOING PHASE 2 STUDY OF IBRUTINIB COMBINED WITH VENETOCLAX IN PATIENTS WITH TREATMENT‐NAÏVE CLL/SLL. Hematological Oncology. 35(S2). 428–428. 1 indexed citations

14.

Jones, Jeffrey A., Peter Hillmen, Steven Coutré, et al.. (2017). Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single‐agent ibrutinib. British Journal of Haematology. 178(2). 286–291. 65 indexed citations

15.

Coutré, Steven, John C. Byrd, Peter Hillmen, et al.. (2016). Integrated and Long-Term Safety Analysis of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL). Blood. 128(22). 4383–4383. 6 indexed citations

16.

Woyach, Jennifer A., Peter Hillmen, Jennifer R. Brown, et al.. (2016). Outcomes of Ibrutinib Therapy By Age in Patients with CLL/SLL: Analyses from Phase 3 Trial Data (RESONATE and RESONATE-2). Blood. 128(22). 2041–2041. 4 indexed citations

17.

O’Brien, Susan, John C. Byrd, Peter Hillmen, et al.. (2016). Outcomes with ibrutinib by line of therapy in patients with CLL: Analyses from phase III data.. Journal of Clinical Oncology. 34(15_suppl). 7520–7520. 13 indexed citations

18.

Hillmen, Peter, Graeme Fraser, Jeffrey A. Jones, et al.. (2015). Comparing Single-Agent Ibrutinib, Bendamustine Plus Rituximab (BR) and Ibrutinib Plus BR in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): An Indirect Comparison of the RESONATE and HELIOS Trials. Blood. 126(23). 2944–2944. 20 indexed citations

19.

Go, Ning, et al.. (2011). Imetelstat, A Potent Telomerase Inhibitor, Inhibits the Spontaneous Growth of CFU-Meg In Vitro From Essential Thrombocythemia Patients but Not From Healthy Individuals,. Blood. 118(21). 3843–3843. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact